Worldwide Countries outside of the United States and Canada.

In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Merck's rights in U.S. patents associated with the relevant product. This list may be a subset of Merck's rights in U.S. patents directed to the relevant product.

Activyl® (indoxacarb) U.S. Patent No. 8,475,818

BOVILIS Nasalgen 3 PMH Live cattle vaccine U.S. Patent No. 9,642,905 U.S. Patent No. 9,662,382

BOVILIS® Coronavirus Live Bovine Coronavirus Vaccine U.S. Patent No. 10,434,168 B2

BRAVECTO® (fluralaner) U.S. Patent No. 7,662,972 U.S. Patent No. 8,796,464 U.S. Patent No. 8,022,089 U.S. Patent No. 8,492,311 U.S. Patent No. 9,173,870 U.S. Patent No. 9,532,978

BRAVECTO® Plus (fluralaner and moxidectin) Topical Solution U.S. Patent No. 9,173,870 U.S. Patent No. 9,532,978

FORTEGRA® Live eimeria vaccine U.S. Patent No. 9,050,281

INNOVAX™ ND-IBD Live virus poultry vaccine U.S. Patent No. 10,308,956

INNOVAX™ ND-ILT Live virus poultry vaccine U.S. Patent No. 8,932,604

Nobivac®: Canine Flu Bivalent Canine influenza virus U.S. Patent No. 7,959,929 U.S. Patent No. 9,345,758 U.S. Patent No. 8,246,962

Nobivac®: Canine Flu H3N8 Canine influenza virus U.S. Patent No. 7,959,929 U.S. Patent No. 9,345,758

Nobivac®: Lyme Borrelia Burgdorferi Bacterin U.S. Patent No. 8,137,678 U.S. Patent No. 8,414,901

Nuflor Gold® Florfenicol U.S. Patent No. 8,034,845

Posatex® Otic Suspension Orbifloxacin, Mometasone Furoate monohydrate and Posaconazole, Suspension U.S. Patent No. 8,084,445 U.S. Patent No. 8,609,645

Prestige® 2 Equine influenza (EIV), equine herpesvirus type 1 (EHV-1) and equine herpesvirus type 4 (EHV-4) U.S. Patent No. 10,555,998

Prestige® 4 Eastern and Western encephalomyelitis (EEE and WEE) viruses, equine influenza virus (EIV) and tetanus U.S. Patent No. 10,555,998

Prestige® 5 Equine herpesvirus type 1 (EHV-1), equine herpesvirus type 4 (EHV-4), Eastern and Western encephalomyelitis (EEE and WEE) viruses, and equine influenza virus (EIV) U.S. Patent No. 10,555,998

Prestige® V+ WNV with Havlogen® Encephalomyelitis-Rhinopneumonitis-Influenza West Nile Virus Vaccine, Eastern and Western, Killed Virus, Killed Flavivirus Chimera, Tetanus Toxoid U.S. Patent No. 8,048,429 U.S. Patent No. 8,133,712 U.S. Patent No. 10,555,998

Resflor Gold® Florfenicol and Flunixin Meglumine U.S. Patent No. 6,790,867 U.S. Patent No. 8,044,102

Zilmax® Zilpaterol hydrochloride U.S. Patent No. 8,580,772 U.S. Patent No. 7,207,289

Zuprevo® Tildipirosin U.S. Patent No. 6,514,946 U.S. Patent No. 8,227,429

BELSOMRA® (suvorexant) Tablets U.S. Patent No. 7,951,797 U.S. Patent No 10,098,892

BRIDION® (sugammadex sodium injection) For intravenous use U.S. Patent No. RE44,733

DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Tablets U.S. Patent No. 8,486,975 U.S. Patent No. 10,603,282 U.S. Patent No. 10,842,751

DIFICID® (fidaxomicin) for Oral Suspension U.S. Patent No. 8,586,551 U.S. Patent No. 7,863,249 U.S. Patent No. 7,378,508 U.S. Patent No. 9,808,530

DIFICID® (fidaxomicin) Tablets for oral use U.S. Patent No. 8,586,551 U.S. Patent No. 7,863,249 U.S. Patent No. 7,378,508

EMEND® (aprepitant) Capsules 125/80 mg U.S. Patent No. 8,258,132

EMEND® (aprepitant) Capsules 40mg U.S. Patent No. 8,258,132

EMEND® (aprepitant) for oral suspension (125 mg) U.S. Patent No. 8,258,132

ISENTRESS® (raltegravir) Chewable Tablets for oral use U.S. Patent No. 7,169,780 U.S. Patent No. 7,754,731

ISENTRESS® (raltegravir) Film-coated Tablets for oral use U.S. Patent No. 7,169,780 U.S. Patent No. 7,754,731

JANUMET® (sitagliptin/metformin HCl) Tablets U.S. Patent No. 6,699,871 U.S. Patent No. 7,326,708 U.S. Patent No. 7,125,873

JANUMET® XR (sitagliptin and metformin HCl extended-release) Tablets U.S. Patent No. 6,699,871 U.S. Patent No. 7,326,708 U.S. Patent No. 7,125,873

JANUVIA® (sitagliptin) Tablets U.S. Patent No. 6,699,871 U.S. Patent No. 7,326,708

JUVISYNC (sitagliptin and simvastatin) Tablets U.S. Patent No. 6,699,871 U.S. Patent No. 7,326,708 U.S. Patent No. 7,125,873 U.S. Patent No. 8,168,637

KEYTRUDA® (pembrolizumab) For Injection U.S. Patent No. 8,354,509 U.S. Patent No. 8,900,587

PIFELTRO™ (Doravirine) Tablets U.S. Patent No. 8,486,975

PREVYMIS™ (letermovir) injection, for intravenous use U.S. Patent No. RE46,791 U.S. Patent No. 8,513,255

PREVYMIS™ (letermovir) Tablets, for Oral Use U.S. Patent No. RE46,791 U.S. Patent No. 8,513,255

RECARBRIO® (imipenem/cilastatin and relebactam) For intravenous use U.S. Patent No. 8,487,093

SEGLUROMET™ (ertugliflozin and metformin) Tablets for oral use U.S. Patent No. 8,080,580

SIVEXTRO® (tedizolid phosphate) Powder for Infusion and Oral tablets U.S. Patent No. 7,816,379 U.S. Patent No. 8,420,676

STEGLATRO™ (ertugliflozin) Tablets for oral use U.S. Patent No. 8,080,580

STEGLUJAN™ (ertugliflozin and sitagliptin) Tablets for oral use U.S. Patent No. 8,080,580

TEMODAR® (temozolomide) for Injection U.S. Patent No. 6,987,108 U.S. Patent No. 7,786,118 U.S. Patent No. 8,623,868

VERQUVO™ VERQUVO™ (vericiguat) tablets, for oral use U.S. Patent No. 8,420,656 U.S. Patent No. 10,736,896

WELIREG™ (belzutifan) U.S. Patent No. 9,908,845 U.S. Patent No. 9,969,689

ZEPATIER® (elbasvir/grazoprevir) Tablets for oral use U.S. Patent No. 8,871,759 U.S. Patent No. 7,973,040

ZERBAXA® (ceftolozane sulfate/tazobactam sodium) Powder for infusion U.S. Patent No. 7,129,232

ZINPLAVA™ (bezlotoxumab) Injection, for intravenous use U.S. Patent No. 8,257,709

ZOLINZA® (vorinostat) Capsules U.S. Patent No. 7,456,219 U.S. Patent No. 7,652,069 U.S. Patent No. 7,851,509 U.S. Patent No. 8,093,295

ERVEBO® EBOLA ZAIRE VACCINE, LIVE U.S. Patent No. 8,012,489B2

GARDASIL® HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, 18) VACCINE, RECOMBINANT U.S. Patent No. 7,476,389

GARDASIL®9 HUMAN PAPILLOMAVIRUS 9-VALENT VACCINE, RECOMBINANT U.S. Patent No. 7,476,389

VAXNEUVANCE™ PNEUMOCOCCAL 15 VALENT CONJUGATE VACCINE Suspension for Intramuscular Injection U.S. Patent No. 8,192,746

Learn how we bring creative minds together as we aim to turn world-class research into impactful medicines and vaccines

Supporting society, people and communities around the world is fundamental to our long-term success

The journey to invention and discovery is guided by science – and inspired by patients

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.